Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company’s technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company’s diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body’s immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Metrics to compare | 0A8I | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship0A8IPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.1x | −2.4x | −0.6x | |
PEG Ratio | 0.00 | −0.12 | 0.00 | |
Price/Book | 0.4x | 1.9x | 2.6x | |
Price / LTM Sales | - | 24.4x | 3.1x | |
Upside (Analyst Target) | - | 168.5% | 57.6% | |
Fair Value Upside | Unlock | 1.4% | 7.3% | Unlock |